A5070830486- Lung Cancer Treatments and Mutations
- Cancer Research and Treatments
- GDF15 and Related Biomarkers
- Folate and B Vitamins Research
- Connective Tissue Growth Factor Research
- Explainable Artificial Intelligence (XAI)
- Radiomics and Machine Learning in Medical Imaging
- Epigenetics and DNA Methylation
- Cell Image Analysis Techniques
- Cancer Cells and Metastasis
- AI in cancer detection
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
AstraZeneca (Germany)
2024
AstraZeneca (United States)
2024
Circulating tumor DNA (ctDNA) positivity at diagnosis, which is associated with worse outcomes in multiple solid tumors including stage I–III non-small cell lung cancer (NSCLC), may have utility to guide (neo)adjuvant therapy. In this retrospective study, 260 patients clinical I NSCLC (180 adenocarcinoma, 80 squamous carcinoma) were allocated (2:1) high- and low-risk groups based on relapse versus disease-free status ≤5 years post-surgery. We evaluated the association of preoperative ctDNA...
Abstract Background: Volrustomig (MEDI5752) is designed to fully inhibit PD-1 while preferentially inhibiting CTLA-4 on activated PD-1+ T cells. In a FTiH trial, volrustomig demonstrated meaningful clinical activity in patients with solid tumors (including 1L RCC and NSCLC), acceptable safety profile, sustained receptor occupancy, cell proliferation at levels greater than seen clinically tolerable doses of inhibitors co-administration anti-PD(L)-1. We sought further characterize...
Abstract Current practice for evaluating prognosis of resectable lung adenocarcinoma (LUAD) patients relies on the Tumor, Node, Metastasis staging system. Despite low relapse risk, post-recurrence survival in a stage I population is poor with median post around 25 months. There need biomarker that can enrich risk to identify likely benefit from adjuvant therapy. In this study, we aim predictive early-stage cancer following surgical resection using AI-based computational pathology. The...